The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Hypokalemic Periodic Paralysis

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Hypokalemic Periodic Paralysis


High impact information on Hypokalemic Periodic Paralysis


Chemical compound and disease context of Hypokalemic Periodic Paralysis


Biological context of Hypokalemic Periodic Paralysis


Gene context of Hypokalemic Periodic Paralysis


Analytical, diagnostic and therapeutic context of Hypokalemic Periodic Paralysis


  1. Angiotensin I level and sporadic hypokalemic periodic paralysis. Umeki, S., Ohga, R., Ono, S., Yasuda, T., Morimoto, K., Terao, A. Arch. Intern. Med. (1986) [Pubmed]
  2. A mutation in the KCNE3 potassium channel gene is associated with susceptibility to thyrotoxic hypokalemic periodic paralysis. Dias Da Silva, M.R., Cerutti, J.M., Arnaldi, L.A., Maciel, R.M. J. Clin. Endocrinol. Metab. (2002) [Pubmed]
  3. The effect of acidosis in hypokalemic periodic paralysis. Jarrell, M.A., Greer, M., Maren, T.H. Arch. Neurol. (1976) [Pubmed]
  4. Treatment of "permanent" muscle weakness in familial Hypokalemic Periodic Paralysis. Dalakas, M.C., Engel, W.K. Muscle Nerve (1983) [Pubmed]
  5. Dynamic alterations in myoplasmic Ca2+ in malignant hyperthermia and central core disease. Lyfenko, A.D., Goonasekera, S.A., Dirksen, R.T. Biochem. Biophys. Res. Commun. (2004) [Pubmed]
  6. Dihydropyridine receptor mutations cause hypokalemic periodic paralysis. Ptácek, L.J., Tawil, R., Griggs, R.C., Engel, A.G., Layzer, R.B., Kwieciński, H., McManis, P.G., Santiago, L., Moore, M., Fouad, G. Cell (1994) [Pubmed]
  7. Impairment of skeletal muscle adenosine triphosphate-sensitive K+ channels in patients with hypokalemic periodic paralysis. Tricarico, D., Servidei, S., Tonali, P., Jurkat-Rott, K., Camerino, D.C. J. Clin. Invest. (1999) [Pubmed]
  8. Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNL1A3): genotype/phenotype correlations for two predominant mutations and evidence for the absence of a founder effect in 16 caucasian families. Elbaz, A., Vale-Santos, J., Jurkat-Rott, K., Lapie, P., Ophoff, R.A., Bady, B., Links, T.P., Piussan, C., Vila, A., Monnier, N. Am. J. Hum. Genet. (1995) [Pubmed]
  9. Sodium channel inactivation defects are associated with acetazolamide-exacerbated hypokalemic periodic paralysis. Bendahhou, S., Cummins, T.R., Griggs, R.C., Fu, Y.H., Ptácek, L.J. Ann. Neurol. (2001) [Pubmed]
  10. Acetazolamide treatment of hypokalemic periodic paralysis. Probable mechanism of action. Vroom, F.W., Jarrell, M.A., Maren, T.H. Arch. Neurol. (1975) [Pubmed]
  11. Hypokalemic periodic paralysis in chronic toluene exposure. Bennett, R.H., Forman, H.R. Arch. Neurol. (1980) [Pubmed]
  12. Intravenous treatment of hypokalemic periodic paralysis. Griggs, R.C., Resnick, J., Engel, W.K. Arch. Neurol. (1983) [Pubmed]
  13. The calcium channel blocker verapamil in hypokalemic periodic paralysis. Links, T.P., Arnoldus, E.P., Wintzen, A.R., van der Hoeven, J., Gerritsen, J.J., Brandenburg, H.C. Muscle Nerve (1998) [Pubmed]
  14. Genetic heterogeneity in hypokalemic periodic paralysis (hypoPP). Plassart, E., Elbaz, A., Santos, J.V., Reboul, J., Lapie, P., Chauveau, D., Jurkat-Rott, K., Guimaraes, J., Saudubray, J.M., Weissenbach, J. Hum. Genet. (1994) [Pubmed]
  15. Thyrotoxic hypokalemic periodic paralysis following second-trimester prostaglandin-induced abortion. Richey, S.D., Wendel, G.D. Obstetrics and gynecology. (1993) [Pubmed]
  16. Identification of mutations in the CACNL1A3 gene in 13 families of Scandinavian origin having hypokalemic periodic paralysis and evidence of a founder effect in Danish families. Sillén, A., Sørensen, T., Kantola, I., Friis, M.L., Gustavson, K.H., Wadelius, C. Am. J. Med. Genet. (1997) [Pubmed]
  17. Hypokalemic periodic paralysis mutations: confirmation of mutation and analysis of founder effect. Grosson, C.L., Esteban, J., McKenna-Yasek, D., Gusella, J.F., Brown, R.H. Neuromuscul. Disord. (1996) [Pubmed]
  18. Mutation screening in Korean hypokalemic periodic paralysis patients: a novel SCN4A Arg672Cys mutation. Kim, M.K., Lee, S.H., Park, M.S., Kim, B.C., Cho, K.H., Lee, M.C., Kim, J.H., Kim, S.M. Neuromuscul. Disord. (2004) [Pubmed]
  19. A novel sodium channel mutation in a family with hypokalemic periodic paralysis. Bulman, D.E., Scoggan, K.A., van Oene, M.D., Nicolle, M.W., Hahn, A.F., Tollar, L.L., Ebers, G.C. Neurology (1999) [Pubmed]
  20. Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. Tawil, R., McDermott, M.P., Brown, R., Shapiro, B.C., Ptacek, L.J., McManis, P.G., Dalakas, M.C., Spector, S.A., Mendell, J.R., Hahn, A.F., Griggs, R.C. Ann. Neurol. (2000) [Pubmed]
  21. Acetazolamide opens the muscular KCa2+ channel: a novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis. Tricarico, D., Barbieri, M., Camerino, D.C. Ann. Neurol. (2000) [Pubmed]
WikiGenes - Universities